Compare CVR & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVR | TCRT |
|---|---|---|
| Founded | 1920 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 7.8M |
| IPO Year | 1995 | 2025 |
| Metric | CVR | TCRT |
|---|---|---|
| Price | $9.85 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.6K | ★ 2.6M |
| Earning Date | 11-06-2026 | 11-24-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,890,260.00 | $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.35 | N/A |
| 52 Week Low | $8.71 | $0.72 |
| 52 Week High | $15.00 | $4.50 |
| Indicator | CVR | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 44.22 |
| Support Level | $9.59 | $1.02 |
| Resistance Level | $10.89 | $2.09 |
| Average True Range (ATR) | 0.56 | 0.18 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 26.67 | 7.81 |
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.